| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Interleukin-2 and regulatory T cells in graft-versus-host disease.
|
N Engl J Med
|
2011
|
6.02
|
|
2
|
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
|
JAMA
|
2009
|
4.08
|
|
3
|
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
|
Biol Blood Marrow Transplant
|
2007
|
3.58
|
|
4
|
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
|
Blood
|
2004
|
2.89
|
|
5
|
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
|
Biol Blood Marrow Transplant
|
2006
|
2.44
|
|
6
|
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
|
Blood
|
2003
|
2.36
|
|
7
|
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.
|
Blood
|
2011
|
2.36
|
|
8
|
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
|
Blood
|
2004
|
2.30
|
|
9
|
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
|
Blood
|
2011
|
2.26
|
|
10
|
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.
|
Blood
|
2012
|
2.19
|
|
11
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
12
|
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
|
J Clin Invest
|
2010
|
2.00
|
|
13
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
14
|
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2006
|
1.99
|
|
15
|
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
|
J Clin Oncol
|
2013
|
1.88
|
|
16
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
17
|
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.85
|
|
18
|
Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.
|
Blood
|
2012
|
1.81
|
|
19
|
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
1.74
|
|
20
|
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
|
Blood
|
2003
|
1.73
|
|
21
|
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
|
J Clin Oncol
|
2012
|
1.68
|
|
22
|
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
|
Blood
|
2004
|
1.58
|
|
23
|
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.
|
Blood
|
2012
|
1.55
|
|
24
|
Validation of measurement scales in ocular graft-versus-host disease.
|
Ophthalmology
|
2011
|
1.50
|
|
25
|
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
|
Biol Blood Marrow Transplant
|
2008
|
1.41
|
|
26
|
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.
|
Biol Blood Marrow Transplant
|
2009
|
1.40
|
|
27
|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
|
Biol Blood Marrow Transplant
|
2010
|
1.39
|
|
28
|
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
|
J Clin Invest
|
2014
|
1.38
|
|
29
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
30
|
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
|
Proc Natl Acad Sci U S A
|
2009
|
1.34
|
|
31
|
Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study.
|
Haematologica
|
2011
|
1.32
|
|
32
|
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
|
J Clin Invest
|
2013
|
1.30
|
|
33
|
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.27
|
|
34
|
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
1.27
|
|
35
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
36
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
37
|
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
|
Blood
|
2012
|
1.15
|
|
38
|
Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.
|
Haematologica
|
2011
|
1.13
|
|
39
|
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.13
|
|
40
|
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
|
Biol Blood Marrow Transplant
|
2009
|
1.13
|
|
41
|
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
|
Blood
|
2009
|
1.12
|
|
42
|
Clinical benefit of response in chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
43
|
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
44
|
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
45
|
Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.09
|
|
46
|
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2013
|
1.08
|
|
47
|
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.
|
Br J Haematol
|
2009
|
1.07
|
|
48
|
How we treat oral chronic graft-versus-host disease.
|
Blood
|
2012
|
1.06
|
|
49
|
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.06
|
|
50
|
Assessment of joint and fascia manifestations in chronic graft-versus-host disease.
|
Arthritis Rheumatol
|
2014
|
1.04
|
|
51
|
Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.
|
Biol Blood Marrow Transplant
|
2013
|
1.01
|
|
52
|
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.00
|
|
53
|
Does iron overload really matter in stem cell transplantation?
|
Am J Hematol
|
2012
|
0.99
|
|
54
|
Medical management update: Non-Hodgkin lymphoma.
|
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
|
2009
|
0.98
|
|
55
|
Donor-derived second hematologic malignancies after cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.98
|
|
56
|
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2013
|
0.96
|
|
57
|
How we treat higher-risk myelodysplastic syndromes.
|
Blood
|
2013
|
0.95
|
|
58
|
Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.
|
J Clin Oncol
|
2011
|
0.92
|
|
59
|
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.90
|
|
60
|
Current and novel therapies in acute GVHD.
|
Best Pract Res Clin Haematol
|
2008
|
0.89
|
|
61
|
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.
|
Biol Blood Marrow Transplant
|
2013
|
0.88
|
|
62
|
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
|
Blood
|
2011
|
0.88
|
|
63
|
Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
64
|
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
|
Ther Adv Hematol
|
2012
|
0.84
|
|
65
|
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
66
|
Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.
|
Biol Blood Marrow Transplant
|
2009
|
0.81
|
|
67
|
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
|
Am J Hematol
|
2014
|
0.80
|
|
68
|
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
|
Am J Hematol
|
2014
|
0.79
|
|
69
|
GVHD prevention: an ounce is better than a pound.
|
Biol Blood Marrow Transplant
|
2012
|
0.79
|
|
70
|
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
|
Biol Blood Marrow Transplant
|
2010
|
0.79
|
|
71
|
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2012
|
0.78
|
|
72
|
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
|
Cancer
|
2004
|
0.77
|
|
73
|
Outcomes and management strategies for graft failure after umbilical cord blood transplantation.
|
Am J Hematol
|
2014
|
0.76
|